Skip to content

NewAmsterdam Pharma Company NAMS Return on invested capital

Return on invested capital at other companies

Merck & Co. logo
Merck & Co.MRK
10.8%-12.8pp
Amgen logo
AmgenAMGN
14.1%+4.0pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
10.3%-2.0pp
Eli Lilly logo
Eli LillyLLY
42%+16.6pp
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-64.8%+100pp

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Calculated from NewAmsterdam Pharma Company’s reported figures.

Based on trailing twelve months.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's return on invested capital?
NewAmsterdam Pharma Company (NAMS) reported return on invested capital of -181.6% in Q1 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.